Le Lézard
Classified in: Health
Subjects: SVY, FDA

New FDA-Approved Nasal Spray Anti-Depressant SPRAVATOtm Now Available in Bay Area at Palo Alto Mind Body

PALO ALTO, Calif., March 14, 2019 /PRNewswire/ --  By age 22, Victor C. had tried everything in his battled against severe depression and was losing hope. Last year he found new hope with intravenous ketamine infusions.  Ketamine lifted his depression. "I felt reborn," he said. "There is no other way to put it. It's indescribable." With the FDA approval of SPRAVATOtm (www.paloaltomindbody.com/services/spravato) ketamine-based nasal spray, others like Victor have new hope in their battle against severe depression.

Victor first benefited from intravenous ketamine infusions administered at Palo Alto Mind Body under the direction of Dr. M Rameen Ghorieshi (www.paloaltomindbody.com/provider/m-rameen-ghorieshi-md-mph).  After initial treatments, Victor transitioned to a maintenance routine involving an off-label ketamine nasal spray. This enabled him to maintain progress made with ketamine infusions and reduce the frequency of booster infusions. FDA's approval of SPRAVATOtm affirms what Victor knows: ketamine-based treatments work.  Furthermore, FDA approval clears the path for patients like Victor to receive support from insurance.

Dr. Ghorieshi, one of the first certified providers of SPRAVATOtm in the Bay Area, is now seeing new patients interested in SPRAVATOtm.   "We've successfully administered over 1000 ketamine treatments to patients with severe depression, anxiety, PTSD, and chronic pain.  The results are tremendously positive," said Dr. Ghorieshi. "This is an amazing opportunity to help a broader range of patients. FDA approval, often followed by insurance coverage, is important to many patients. Additionally, the nasal spray is a great alternative for those uneasy about receiving infusions." 

After more than 1000 IV ketamine treatments (www.paloaltomindbody.com/services/iv-ketamine-infusions), Dr. Ghorieshi reports that 87% of patients have experienced significant improvement and 35% of those consider the improvement to be "life-changing."

In August 2018, Victor hoped to return to college. With ketamine, he took control of his life, returned to school, and finished with a 3.9 average.  "I know many people struggling with depression who don't know what to do. I now have confidence that there's a future," he said.

Palo Alto Mind Body with Janssen CarePath helps patients understand affordable options to seek treatment with SPRAVATOtm including insurance verification and discounts.

Palo Alto Mind Body
550 Hamilton Avenue, Ste. 215
Palo Alto, CA 94301


SOURCE Palo Alto Mind Body

These press releases may also interest you

at 03:00
MedAlliance has announced enrollment of the first patient in its study of SELUTION SLRtm 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Program'. The SELUTION SLR (Sustained...

at 03:00
Uniform Advantage (UA), a multi-channel retailer of medical uniforms for medical and hospitality industries, develops an innovative exclusive scrub collection for men and women, focused on comfort, durability and functionality. "We designed Movement...

10 jui 2020
Johns Hopkins University filed suit in federal court Friday in an effort to stop a Trump administration rule change that would severely impact nearly 5,000 international students at the university. The decision to abruptly rescind accommodations for...

10 jui 2020
Worries and anxiety about COVID-19 and its impact can be overwhelming for people with spinal cord disease or injury and social distancing makes it even more challenging. "For folks with a spinal cord injury, the COVID-19 pandemic can induce symptoms...

10 jui 2020
Lincoln International is pleased to announce that The Araz Group, Inc. (d/b/a HealthEZ), a leading independent third-party administrator (TPA) of self-funded medical plans, has received an investment from Abry Partners LP, a private investment firm...

10 jui 2020
MPX International Corporation ("MPX International", "MPXI" or the "Corporation") today reports financial results for its second quarter, the three and six month period ended March 31, 2020. All figures are presented...

News published on 14 march 2019 at 14:12 and distributed by: